Current approaches for biomarker use in precision medicine are slow, expensive, and variable, leading to inefficient and inadequate delivery of personalized treatments.

ViewsML's vision is to harness the power of AI to bring precision medicines faster and to more patients worldwide. Our mission is to create the world's first foundational AI virtual biomarker library for research scientists and clinicians. By virtualizing immunohistochemistry (IHC) and in turn biomarkers - and thus bypassing this wet lab process - we give researchers back 100% of their IHC time, 50% of their budget and richer data sets. We allow for better drug characterization through virtual multiplexing, more precise patient selection in clinical trials, and virtualization of clinical diagnostic assays to more efficiently identify and triage patients for treatment.